ReviewChemistry & biodiversity2026
A 5-Year Survey on Multiple Targeted Benzimidazole Hybrids.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among heterocyclic compounds, the various biological activities and the easily modifiable chemical structure of benzimidazole compounds make them important in drug development. Currently, the demand for treatments targeting multiple biological pathways is increasing. In the treatment of multifaceted diseases, drugs exhibiting multiple therapeutic effects and low toxicity are particularly advantageous. In this context, the ability of benzimidazole compounds to form hybrid structures that target multiple biological mechanisms is noteworthy. In this review, studies on the multifaceted biological activities of hybrid benzimidazole derivatives-including benzimidazole-triazole, benzimidazole-thiazole, benzimidazole-oxadiazole, benzimidazole-quinoline, benzimidazole-hydrazone, benzimidazole-benzimidazole, benzimidazole-thiadiazole, benzimidazole-piperazine, benzimidazole-imidazole, benzimidazole-benzothiazole, benzimidazole-coumarin, benzimidazole-indole, benzimidazole-Schiff base and benzimidazole-urea reported in the literature over the past 5 years are discussed. In addition, this review also examines molecular modeling and structure-activity relationship studies to elucidate their therapeutic potential, highlighting the contribution of hybrid benzimidazole derivatives to the development of effective drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.